Castle BiosciencesCSTL
CSTL
About: Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Employees: 784
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
79% more call options, than puts
Call options by funds: $200K | Put options by funds: $112K
39% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 54
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
3.92% less ownership
Funds ownership: 94.38% [Q4 2024] → 90.47% (-3.92%) [Q1 2025]
9% less funds holding
Funds holding: 196 [Q4 2024] → 179 (-17) [Q1 2025]
27% less capital invested
Capital invested by funds: $705M [Q4 2024] → $515M (-$190M) [Q1 2025]
30% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 43
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$35
87%
upside
Avg. target
$37
99%
upside
High target
$40
113%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Scotiabank Sung Ji Nam | 113%upside $40 | Sector Outperform Maintained | 21 May 2025 |
Lake Street Thomas Flaten | 87%upside $35 | Buy Maintained | 6 May 2025 |
Canaccord Genuity Kyle Mikson | 97%upside $37 | Buy Maintained | 6 May 2025 |
Financial journalist opinion
Based on 4 articles about CSTL published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
FRIENDSWOOD, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, founder, president and chief executive officer of Castle Biosciences, will participate in a panel discussion alongside other industry leaders during the 2025 BIO International Convention (BIO 2025), being held June 16-19 in Boston. The panel will explore the challenges precision medicine companies face in commercializing innovative diagnostic tests and discuss strategies for navigating today's market complexities while remaining focused on improving care for patients.
Neutral
GlobeNewsWire
1 week ago
Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
Gold-level Stevie® Award recognizes Maetzold's transformative leadership in the healthcare industry, including molecular diagnostics and precision medicine FRIENDSWOOD, Texas, June 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been awarded a distinguished Lifetime Achievement Award in the Management: Business Products Industries category in the 23rd Annual American Business Awards. The American Business Awards recognizes outstanding business performances in the United States.
Neutral
GlobeNewsWire
2 weeks ago
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
FRIENDSWOOD, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present novel research aimed at enhancing the clinical management of patients with cutaneous melanoma (CM) and uveal melanoma (UM) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30-June 3, 2025, in Chicago. This includes the latest findings from Castle's ongoing collaboration with the National Cancer Institute's Surveillance, Epidemiology and End Results (NCI's SEER) Program Registries affirming the significant, independent risk stratification provided by DecisionDx-Melanoma in an expanded, real-world cohort of more than 13,500 patients who received the test as part of their melanoma care.
Neutral
GlobeNewsWire
3 weeks ago
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
Castle's executive management will present a company overview at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 7:35 am ET
Neutral
GlobeNewsWire
1 month ago
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
FRIENDSWOOD, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the first independent validation of the recently published Collaborative Ocular Oncology Group Study No. 2 (COOG2.1) by Harbour et al.1 The data, from a real-world cohort of 1,297 patients with uveal melanoma (UM), was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City.
Neutral
GlobeNewsWire
1 month ago
Castle Biosciences Celebrates Skin Cancer Awareness Month
Castle continues its ongoing patient advocacy partnerships and highlights cancer journey to drive education and awareness for Skin Cancer Awareness Month
Neutral
Seeking Alpha
1 month ago
Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Camilla Zuckero - Vice President of Investor Relations and Corporate Affairs Derek Maetzold - Founder, President & Chief Executive Officer Matthew Goldberg - Senior Vice President, Medical Frank Stokes - Chief Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Kyle Mikson - Canaccord Puneet Souda - Leerink Partners Tom Peterson - Baird Paul Knight - KeyBanc Capital Markets Subbu Nambi - Guggenheim Mason Carrico - Stephens Thomas Flaten - Lake Street Mark Massaro - BTIG Operator Good afternoon and welcome to Castle Biosciences First Quarter 2025 Conference Call. As a reminder, today's call is being recorded.
Negative
Zacks Investment Research
1 month ago
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.09 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Castle Biosciences Reports First Quarter 2025 Results
Q 1 2025 revenue increased 21% over Q 1 2024 to $88 million Q 1 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, DecisionDx ® -SCC, TissueCypher ® ) increased 33% over Q 1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2025.
Neutral
GlobeNewsWire
1 month ago
Castle Biosciences to Acquire Previse
Expected to complement Castle's current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire Capsulomics, Inc., d/b/a Previse. Previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases, including esophageal cancer.
Charts implemented using Lightweight Charts™